MARIPOSA

The MARIPOSA Research Study

An Overview for Healthcare Professionals

The information contained in this download is intended for healthcare providers only.
This is not to be used with potential participants.

About the MARIPOSA Study

The purpose of the MARIPOSA research study is to evaluate the combined efficacy of the investigational medications, amivantamab and lazertinib in adults with newly diagnosed locally advanced or metastatic non-small-cell lung cancer (NSCLC) that have epidermal growth factor receptor (EGFR) Exon 19 deletion or Exon 21 L858R substitution mutations.

- Amivantamab and Lazertinib are being evaluated in combination as a first-line treatment compared to both Osimertinib and Lazertinib as monotherapies

Your patients may be eligible if they meet the following inclusion criteria:

- ≥ 18 years of age
- New histologically or cytologically confirmed, locally advanced or metastatic NSCLC not amenable to curative therapy
- A tumor determined to have Exon 19 deletion or Exon 21 L858R substitution *
- Have not received any prior systemic treatment for locally advanced or metastatic disease
- Have not received any prior treatment with an EGFR TKI
- Have not received an investigational agent, adjuvantor neoadjuvant therapy within 12 months of developing locally advanced or metastatic disease, or be currently enrolled in an investigational study
- Sufficient unstained tumor tissue both collected at or after the diagnosis of locally advanced or metastatic NSCLC (must be provided)
- Resolution of any toxicities from prior anticancer therapy
- At least 1 measurable lesion, according to RECIST v1.1
- ECOG performance status of 0 or 1
- Must demonstrate adequate organ and bone marrow function

**A copy of the newly obtained local mutation confirmation report must be provided and provision of the tumor biopsy sample obtained for the diagnosis of advanced disease is required*

MARIPOSA

What will happen during the MARIPOSA Study?

- Eligible patients will be randomized 2:2:1 to Arms A, B, and C, respectively.
  - Patients in Arm A will receive the investigational combination of amivantamab (intravenous infusion) and lazertinib (orally, once daily). The infusions of amivantamab will be given weekly for the first four weeks, followed by once every two weeks
  - Patients in Arm B will receive osimertinib (orally, once daily)
  - Patients in Arm C will receive lazertinib (orally, once daily)
- All patients will go through 28-day cycles with their study medication
- A patient's total study participation will last up to approximately five years. However, the length of participation will depend on the response to study medication
- Participation also includes regularly scheduled study visits for tests and procedures

The planned study duration will vary from person to person. Each study participant will continue on 28-day treatment cycles until their NSCLC progresses, unacceptable toxicity, the study ends, or they discontinue for other reasons.

There are study clinics located throughout the United States. Find a location near you by visiting
https://janssenoncologyclinicaltrials.com/lc/locations

To see a list of participating study clinics in over 20 countries globally, visit
https://janssenoncologyclinicaltrials.com/lc/countries

If you have a patient with EGFR Exon 19 deletion or Exon 21 L858R substitution mutations who may be a candidate, speak to them about the possibility of participating in this research study.

Have your patients call 1-800-811-1923 or visit
JanssenOncologyClinicalTrials.com/lungcancer
to see if they are eligible and to learn more about the MARIPOSA Study.

Janssen Research & Development, LLC
73841937NSC3003_ENG17
Version 1.0, 05June2020

janssen Oncology
PHARMACEUTICAL COMPANIES OF Johnson&Johnson